Molbio Diagnostics delivery percentage & share price.
· data for the trading session of Wed 18 Nov 2026
Price, volume and delivery
Candles adjusted for splits and bonuses. In the lower panel, the grey bar is the day’s volume and the coloured bar is the part that was delivered; bright green marks big-buyer days (delivered shares 3× the stock’s normal or more, with a normal-or-higher delivery %).
Molbio Diagnostics share price today: what happened on 18 November
Written from NSE’s end-of-day data for 18 Nov 2026. Updated every trading evening. Facts, not advice.
Molbio Diagnostics ended up at ₹1,497.60 on Wednesday, 18 November 2026, up ₹13.50 or 0.91% from the previous close of ₹1,484.10. It opened at ₹1,499.00 and traded between ₹1,458.00 and ₹1,517.30, a range of 4.0% of its price, and finished in the middle of it. The day began with a 1.0% gap up, which was filled during the session.
It closed higher on 5 of the last 10 sessions and is +8.4% over that stretch. Looking further back: one week +13.6%, one month +4.4%, three months +44.5%.
3.57 lakh shares changed hands, worth about ₹53.3 crore, 0.4 times the 20-session average, a quieter day than usual. Of those, 19% (68,291 shares) were taken for delivery, meaning they actually changed owners instead of being traded within the day. That compares with a 60-session average of 19%. There were no big-buyer days (delivery several times above normal) in the last three months.
The close is 10.1% above the 50-day average of ₹1,359.62. The 14-day RSI, a 0–100 gauge of recent momentum, reads 61, in the neutral zone between 30 and 70. It sits 11.2% below its 52-week high of ₹1,686.80 and 61.7% above the low of ₹926.35, in the upper part of the year’s range.
Looking at where shares were actually delivered over the past year, the busiest price zone below today’s close is around ₹1,470 (-1.9%). Prices often slow down near such zones because many holders bought there, but they are history, not predictions.
On a typical day Molbio Diagnostics moves about ±5.3%, and its average session spans 7.2% from high to low. It closed higher on 47% of the sessions since listing (65 sessions). It opened with a gap of 1% or more 19 times in that time (15 up, 4 down). Its best day since listing was 10 September 2026 (+19.99%) and its worst was 19 October 2026 (-8.87%).
Last five sessions
| Day | Close | Change | Volume | Delivery |
|---|---|---|---|---|
| Wed 18 Nov | ₹1,497.60 | +0.91% | 3.57 lakh | 19% |
| Tue 17 Nov | ₹1,484.10 | -0.15% | 4.88 lakh | 17% |
| Mon 16 Nov | ₹1,486.40 | -0.46% | 5.67 lakh | 19% |
| Fri 13 Nov | ₹1,493.20 | +7.11% | 23.04 lakh | 13% |
| Thu 12 Nov | ₹1,394.10 | +5.73% | 22.77 lakh | 11% |
Price levels by delivered volume
Where the most Molbio Diagnostics shares were actually delivered over the last year. Each day’s delivered shares are spread across that day’s high–low range; the peaks are the busiest price zones. Below the close: support zones; above: resistance zones. History, not a forecast.
- Last close₹1,497.6018 Nov
- Support 1₹1,470-1.9% · 5.1% of the year’s delivery
- Support 2₹1,275-15.0% · 5.5% of the year’s delivery
- Support 3₹1,065-28.9% · 5.0% of the year’s delivery
Molbio Diagnostics IPO
How the Molbio Diagnostics IPO listed and what the share did after. Full IPO page: subscription, listing day and returns after listing →
Its listing gain beat 73% of the 227 main-board IPOs since Oct 2024. How IPOs usually do after listing →
Molbio Diagnostics at a glance
- Molbio Diagnostics closed at ₹1,497.60 on 18 Nov 2026 (+0.91% on the day).
- It trades 11.2% below its 52-week high of ₹1,686.80 and 61.7% above its low of ₹926.35.
- 19% of the shares traded on 18 Nov were delivered, against a 60-session average of 19%.
- There were no big-buyer days (delivery far above normal) in the last three months.
- A typical day moves it about ±5.3%: calmer than 100% of the 1,443 most traded NSE stocks.
Molbio Diagnostics pros and cons
Written automatically from the latest results, shareholding, valuation against its sector, and price and delivery data. Facts, not advice.
Pros
- Mutual funds raised their stake by 5.8 points last quarter, to 8.0%.
Cons
- Nothing stands out.
Molbio Diagnostics fundamentals
Quarterly results and shareholding from NSE filings. Profit is the share owed to the company’s own shareholders. Compare in the stock screener →
Revenue
₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.
Net profit
₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.
Who owns Molbio Diagnostics
Shareholding pattern for the quarter to 30 Sep 2026, from the company’s filing with NSE.
Change since Aug 2026:
Molbio Diagnostics balance sheet, returns and cash flow
From the consolidated half-year and annual results filed with NSE (latest: 30 Sep 2026), on the same basis as the quarterly figures above.
| Sep 2026half year | |
|---|---|
| Shareholders’ equity | ₹1,440 Cr |
| Borrowings (excl. leases) | ₹352 Cr |
| Cash, bank balances & current investments | ₹569 Cr |
| Operating cash flow | ₹167 Cr |
| Capex (PPE + intangibles) | ₹33.6 Cr |
Balance sheet items are as at the date shown; cash flows cover the half year or full year to that date. ₹ crore.
Delivery and big-buyer days
Delivered shares change owners for real; intraday trades don’t. Days when delivery jumps far above normal often mean large investors were buying or selling.
Delivery calendar, last 12 months
Each square is a session. The brighter the green, the more shares were delivered compared with Molbio Diagnostics’s normal. Hover or tap a square for the day.
Molbio Diagnostics timeline
Everything that happened to Molbio Diagnostics, newest first: deals, promoter filings, results, big-buyer days, new highs and big moves.
- October 2026
- 29 OctLarge holder Kotak Mahindra Mutual Fund bought 5.70 L shares0.49% of the company (Open Market); holds 5.48% after. Filed with NSE.
- 12 OctLarge holder India Business Excellence Fund Iii sold 30.00 L shares2.60% of the company (Open Market); holds 8.92% after. Filed with NSE.
- 8 OctLarge holder India Business Excellence Fund Iii, A Scheme Of Business Excellence Trust Iii sold 23.78 L shares2.06% of the company (Open Market); holds 6.85% after. Filed with NSE.
- 1 OctLarge holder India Business Excellence Fund Iii, A Scheme Of Business Excellence Trust Iii sold 30.00 L shares2.60% of the company (Open Market); holds 8.92% after. Filed with NSE.
- September 2026
- 10 SepJumped 20.0% in one sessionClosed at ₹1,509.40, about 3.8× a normal day’s move.
My notes on Molbio Diagnostics
Private: saved only in this browser, never sent to us.
Questions
What is the 52-week high and low of Molbio Diagnostics?
What is the delivery percentage of Molbio Diagnostics?
How volatile is Molbio Diagnostics?
What is the market cap of Molbio Diagnostics?
Who owns Molbio Diagnostics? What is its shareholding pattern?
Is Molbio Diagnostics debt free?
What is the book value of Molbio Diagnostics?
What are the support and resistance levels of Molbio Diagnostics?
What was the IPO price of Molbio Diagnostics?
Data from NSE’s daily files, adjusted for splits and bonuses. Past behaviour is not a forecast. This is information, not investment advice; ChartMine is not a SEBI-registered adviser.
